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The structural genes of adeno-associated virus serotype 2 (AAV2) have been altered by linker insertional mutagenesis in
order to define critical components of virion assembly and infectivity. An in-frame restriction site linker was inserted across
the capsid coding domain of a recombinant plasmid. After complementation in vivo, recombinant AAV2 viruses were
generated and assayed for capsid production, packaging, transduction, heparin agarose binding, and morphology. Three
classes of capsid mutants where identified. Class I mutants expressed structural proteins but were defective in virion
assembly. Class II mutants generated intact virions that protected the viral genome from DNase, but failed to infect target
cells. The majority of these mutants bound the heparin affinity matrix, suggesting that attachment to the AAV primary
receptor was not rate limiting. One class II mutant, H2634, assembled virions and bound heparin using only Vp3, indicating
that this subunit is responsible for mediating AAV receptor attachment. Finally, class III mutants assembled virions,
encapsidated DNA, and infected target cells. Infectivity of these mutants ranged from 5 to 100% of that of the wild-type,
demonstrating for the first time the ability to alter capsid proteins without interfering with infectivity. These AAV virions with
altered capsid subunits will provide critical templates for manipulating AAV vectors for cell-specific gene delivery in vivo. In
summary, the AAV capsid variants described here will facilitate further study of virus assembly, entry, and infection, as well
as advance the development of this versatile vector system. © 1999 Academic Press
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Adeno-associated virus serotype 2 (AAV2) is a small
onenveloped virus in the parvoviridae family that re-
uires a helper virus, adenovirus or herpesvirus, for
fficient productive infection (Casto et al., 1967; McPher-
on et al., 1985). AAV2 packages a 4681-nucleotide (Sriv-
stava et al., 1983) genome of both positive and negative
olarity (Berns and Adler, 1972; Berns and Rose, 1970;
ose et al., 1969) into a 20- to 25-nm virion with icosa-
edral symmetry (Atchison et al., 1965; Hoggan et al.,
966). The viral DNA consists of two open reading
rames flanked by inverted terminal repeats. The right
pen reading frame, which is expressed from the p40
romoter, codes for three structural proteins Vp1, Vp2,
nd Vp3. The regions that encode the three capsid genes
hare overlapping reading frames. The capsid genes are
egulated by alternative splicing (Vp1) and translational
nitiation (ACG for Vp2 and AUG for Vp3) during a pro-
uctive infection (Becerra et al., 1988; Muralidhar et al.,
994; Su et al., 1996; Trempe and Carter, 1988). After
ranslation, the capsid proteins migrate to the nucleus
nd assemble into progeny virions. The virions are com-
osed of 60 subunits with a stoichiometry of 1:1:20 for
1 To whom reprint requests should be addressed at Gene Therapy
enter, University of North Carolina at Chapel Hill, 7119 Thurston-
owles CB7352, Chapel Hill, NC 27599-7352. Fax: (919) 966-0907.l-mail: rjs@med.unc.edu.
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274p1, Vp2, and Vp3, respectively (Rose et al., 1971). The
atio of virion capsid subunits correlates with in vivo
xpression levels seen during productive infection.
Early studies of AAV2 support the idea that all three
apsid subunits are required to extract single-stranded
enomes from the pool of replicating double-stranded
NA. These genomes are then sequestered into pre-
ormed immature particles that maturate to infectious
articles. These particles have a density between 1.32
nd 1.41 g/mL in cesium chloride and sediment between
0 and 125S in sucrose (Myers and Carter, 1981; Myers
t al., 1980). Mutagenesis studies of AAV2 capsids have
hown that insertions and deletions in the Vp3 domain
ompletely inhibit the accumulation of single-stranded
irions and production of infectious particles (Hermonat
t al., 1984; Ruffing et al., 1994). Missence mutagenesis
f Vp1, Vp2, and Vp3 initiation codons resulted in no
ccumulation of single-stranded template or production
f infectious particles (Muralidhar et al., 1994), suggest-
ng an essential role for the individual capsid subunits
uring a productive infection. In contrast, it has been
hown that a 186-bp XhoI deletion in the unique coding
egion of Vp1 does not inhibit accumulation of single-
tranded template, but results in low infectious particles
Hermonat et al., 1984; Janik et al., 1984; Tratschin et al.,
984). The use of an amber mutation, which decreased
roduction of Vp1 to 5% of wild-type levels in an amber
uppressor cell line, was still sufficient for the accumu-ation of single-stranded DNA and production of infec-
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275AAVZ MUTAGENESIS AND VIRUS PRODUCTIONious particles (Smuda and Carter, 1991). In fact 45% of
he Vp1 unique region can be deleted or .90% of the
rotein depleted using the amber suppressor mutation
nd low infectious particles still form (Hermonat et al.,
984; Janik et al., 1984; Smuda and Carter, 1991;
ratschin et al., 1984). These studies suggest that accu-
ulation of single-stranded DNA requires the presence
f Vp1 but the levels may be variable and insertions and
eletions can be tolerated. While mutant analysis of the
ep coding region has been more extensive than that of
he capsid coding region, the above analyses have been
nformative about the role of structural proteins in AAV
ssembly.
In fact, now several studies have demonstrated that
arvovirus capsid proteins can be mutated and virion
ssembly studied. In one study, the coding region for 147
mino acids of the hen egg white lysozyme was substi-
uted for the B19 Vp1 unique coding sequence. This
odification resulted in purified empty particles that re-
ained lysozyme enzymatic activity (Miyamura et al.,
994). In addition, expression of peptides (9 and 13 res-
dues) in B19 Vp2 resulted in empty particles that were
mmunogenic in mice supporting surface presentation of
he insertions (Brown et al., 1994). In a more recent study,
he CD8 1 CTL epitope (residues 118–132) against lym-
hocytic choriomeningitis virus (LCMV) nucleoprotein
as inserted into the Vp2 capsid protein of porcine
arvovirus (ppv) (Sedlik et al., 1997). This capsid protein
ith the epitope cloned at the N-terminus self-assem-
led when expressed in a baculovirus system. This chi-
eric virus-like particle was then used to immunize mice
gainst a lethal challenge from LCMV (Sedlik et al.,
997). These studies establish the flexibility of the B19
nd ppv capsids when foreign sequences are inserted
nto domains outside the predicted core b-barrel motif
hen using empty particles.
The identification of domains that are responsible for
AV2 host range, binding to the major cell surface re-
eptor, and domains that can accommodate insertions
ithout loss of function is important for a virus that is
eing considered as a candidate vector for human gene
herapy. Mutagenesis along with a crystal structure
hould provide sufficient details to characterize the role
f the AAV structural subunits in virion assembly and
nfectivity. However, in the absence of a crystal structure,
e have used linker insertion mutagenesis to isolate a
ollection of mutants throughout the capsid coding re-
ion. Using Western blot, electron microscopy (EM) anal-
sis, DNase protection, and virion transduction assays,
e have identified three classes of insertion mutants.
lass I mutants are defective for virions assembly and/or
tability. Class II mutants protect viral DNA from DNase
igestion but are not infectious, while class III mutants
xpress foreign peptides and maintain morphology, sta-
ility, and infectivity of the wild-type virion. This unique
ssortment of viable insertion mutants will be critical 1eagents for studying AAV assembly and infectivity as
ell as serve as templates for the development of tar-
eting AAV vectors for human gene therapy.
RESULTS
onstruction of insertional mutations in rAAV2
In order to evaluate the role of AAV structural proteins
n assembly and infectivity, we generated a collection of
apsid linker insertion mutants. A 2.8-kb HindIII fragment
f pAAV/Ad (Samulski et al., 1989) containing the se-
uences coding for the capsid domain of AAV2 was
ubcloned into pBS1. This plasmid, pAV2Cap, was used
or partial digestion with HaeIII, NlaIV, and RsaI to gen-
rate a substrate for capsid-specific insertions (Fig. 1).
hese three DNA restriction enzymes constitute 43 sites
hat span the AAV-2 capsid coding sequence, of which
nly 4 overlap. To efficiently identify clones that contain
nsertions, a kanamycin resistance gene (Kanr) flanked
y a novel oligo (NaeI/EcoRV) was ligated with partially
igested, full-length, linearized pAV2Cap (see Materials
nd Methods for details and Fig. 1). Using ampicillin and
anamycin selection in Escherichia coli, insertion mu-
ants were identified and the Kanr gene was shuttled out
f the capsid coding region by digesting and religation
ith the nested pair of EcoRV sites (see Materials and
ethods). This resulted in a specific linker insertion of
2-bp carrying a single copy of the unique EcoRV site in
he capsid coding sequences. The exact positions of the
inker insertion were further refined by restriction enzyme
igestions and, in six cases, sequencing (data not
hown). The position of insertion mutants are identified
y the first letter of the enzyme used in the partial
igestion followed by the nucleotide position of the re-
triction site in the AAV2 genome, for example, NlaIV
160 would be N4160.
The capsid coding sequence from these mapped in-
ertion mutants were subcloned into the helper vectors
ACG2 or pAAV/Ad for biological characterization in vivo
Fig. 1) (Li et al., 1997; Samulski et al., 1989). Sequence
nalysis predicts that this 12-bp insertion cannot result in
termination codon for any of the 43 insertion sites
Table 1). Owing to the random nature of the cut site for
he enzymes (HaeIII, NlaIV, and RsaI) with respect to
odon frame usage and the degeneracy of the NlaIV
ecognition sequence, the 12-bp linker resulted in the
nsertion of the amino acids GDIA in frame 1 and AISP in
rame 3 for all three enzymes, while insertions in frame 2
esulted in WRYRH for RsaI, GRYRP for HaeIII, and both
RYRP and GRYRH for NlaIV. The bold-faced amino
cids in these examples represent missense mutations
Table 1). The mutant helper constructs, pACG2IN, were
ndividually transfected into 293 cells along with an AAV
eporter vector, containing the b-galactosidase gene in
denovirus dl309 (M.O.I. 5 5)-infected cells (Li et al.,
997). The transfected cells were then assayed for cap-
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276 RABINOWITZ, XIAO, AND SAMULSKIid expression and recombinant virus production (see
aterials and Methods) (Li et al., 1997).
nalysis of capsid proteins
Before assaying for vector production using mutant
apsid constructs in complementation assays, each in-
ertion mutant was tested for expression of capsid sub-
nits in 293 cells after transfection. The ability to produce
p1, Vp2, and Vp3 at normal stoichiometry would suggest
hat linker insertions did not alter capsid protein expres-
ion or stability. Since the linker did not introduce stop
odons, it was expected that each insert would produce
ll three capsids. Forty-eight hours after transfection, cell
ysates were analyzed by Western blot for AAV capsids.
he Western blot analysis in Fig. 2 is a representation of
nsertion mutant capsid expression in cell lysates. With
he exception of H2634 (Fig. 2, lane 2), the stoichiometry
f the three capsid subunits does not appear signifi-
antly different than that of wild-type controls (Fig. 2
ompare lanes 1, 3–7 to lane 8). By this assay, insertion
utant H2634 appears to produce only Vp3 subunits
Fig. 2, lane 2). In longer exposures, the minor capsid
ubunits in Fig. 4, lanes 4 and 5, were apparent (data not
hown).
utant capsid ability to produce stable virions
To test for the production of stable virions that protect
FIG. 1. Insertional mutagenesis strategy for AAV2 capsid. A cassette
he plasmid pAV2Cap. pAV2Cap, which contains the open reading frame
o that unit-length products were isolated. The 43 positions of restrictio
eading frame. The position of the Kanr insert was mapped by restricti
etermined the Kanr gene was removed by EcoRV digestion, and the ca
ragment, with half the NaeI sites flanking a unique EcoRV site, into the
ne of which is shown above the diagram of pACG2.vector genome from DNase digestion, we subjected mhe cell lysates to cesium chloride (CsCl) gradient cen-
rifugation. Virus densities were measured by refractom-
try, and aliquots from appropriate fractions were sub-
ected to dot blot hybridization (Fig. 3A). Based on this
nalysis, particles that package intact recombinant ge-
omes should display a buoyant density similar to that of
he wild-type and be resistant to DNase treatment, with
he exception of H2944, which has a buoyant density
lightly higher than that of the wild-type. Results for this
ssay separated insertion mutants into two classes.
lass I mutants were negative for protecting the viral
enome, while class II mutants appeared normal for
ackaging and protecting the vector substrate (Table 1).
All class II mutants had a buoyant density within the
ange of that of wild-type AAV2 capsids (Fig. 3A). By dot
lot analysis, N2944 packaged the recombinant genome
ut migrated to a position of slightly greater density than
ild-type in isopycnic gradients (Fig. 3A, N2944, lane 3).
number of insertion mutants (7) did not package DNA
y this assay, which had a sensitivity of ,1 3 105
articles/ml (see Materials and Methods for quantitation)
Table 1). Whether these mutants were defective in pack-
ging or unstable during purification remains to be de-
ermined.
nfectivity of class II insertion mutants
Virions generated by insertion mutants in the comple-
ning the kanr gene flanked by EcoRV and NaeI sites were cloned into
2 capsid, was partially digested with HaeIII, NlaIV, and RsaI separately
for these enzymes are shown above the diagram of the capsid open
yme digestion and in some cases sequenced. Once the position was
main subcloned into pACG. This strategy resulted in inserting a 12-bp
tive HaeIII, NlaIV, and RsaI sites. The 12 bp code for four amino acids,contai
of AAV
n sites
on enz
psid do
respecentation assay were tested for infectivity by monitoring
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277AAVZ MUTAGENESIS AND VIRUS PRODUCTIONransduction of LacZ reporter gene in human cells. Using
iral titers derived from dot blot hybridization, HeLa cells
ere infected with mutant virus stocks at equivalent
article numbers. Twenty-four hours postinfection, ex-
ression of the transgene was detected by X-gal stain-
ng. A representative figure of this analysis is shown (Fig.
B) and all mutants assayed are presented in Table 1. In
his assay, wild-type virions transduced 5.6 3 105 HeLa
ells/1.75 3 108 protected particles (Fig. 3B and Materi-
ls and Methods). Based on the sensitivity of this assay,
he range of infection efficiency for class II insertion
T
Physical Structure and Phenoty
ositiona
inserted
Capsid
subunit Frameb Dot blotc Infec
2285 VP1 3 2.8 3 107 2
2356 VP1 2 1.4 3 108 1
2364 VP1 1 — 2
2416 VP1 2 1.4 3 107 2
2591 VP1 3 1.4 3 107 1
2634 VP2 1 2.8 3 107 2
2690 VP2 3 7.0 3 106 1
2747 VP2 3 — 2
/N2944 VP3 2 1.4 3 106 1
3317 VP3 3 1.4 3 105 2
3391 VP3 2 — 2
3561 VP3 1 — 2
3595 VP3 2 1.4 3 106 1
/N3761 VP3 3 1.4 3 107 2
3766 VP3 2 2.8 3 107 2
4046 VP3 3 — 2
/N4047 VP3 1 — 2
/R4160 VP3 3 1.4 3 107 1
a The letter refers to the restriction enzyme used in the partial digest
equence.
b Reading frame of the restriction site.
c The particle number per microliter of sample. (2) 5 ,105 genome
d Infections were done using 1.75 3 108 particles of rAAV insertion m
e By batch binding and assayed by infection of HeLa cells (class III)
f Amino acids differ depending on the frame of the insertion. The am
g Infectious only when purified using Iodixanol.
FIG. 2. Expression of capsid proteins in cells transfected with wild-typ
ransfected with 1, H2285; 2, H2634; 3, H2690; 4, N2944; 5, H2944; 6, H
nd immunoblotting with the B1 monoclonal antibody and detected by p
he positions of the molecular weight standards and on the right are th
P2 and VP1.utant viruses was from 0 to 1.6 3 106 transducing
nits/1.75 3 108 protected particles. Results from this
nalysis further subdivided the capsid insertion mutants
rom class II (normal for packaging and protecting the
ector substrate) into a class III phenotype (normal for
ackaging and protecting the vector substrate and infec-
ious virions). Two insertion mutants negative for infec-
ivity and initially identified as class II mutants (N2944,
3595) based on CsCl purification and DNase protection
ested positive for viral transduction after purification
sing an iodixanol step gradient (Table 1). This virus
AV2 Capsid Insertion Mutants
Heparin
agarosee
Electron
microscope Phenotype
Amino
acid f
1 Normal Class II AISP
1 N.D. Class III WRYRH
N.D. N.D. Class I GDIA
1 N.D. Class II GRYRP
1 Normal Class III AISP
1 Normal Class II GDIA
1 Normal Class III AISP
N.D. N.D. Class I AISP
N.D. N.D. Class II/III GRYRP
N.D. N.D. Class II AISP
N.D. N.D. Class I WRYRH
N.D. N.D. Class I GDIA
N.D. Abnormal Class II/III GRYRP
2 Normal Class II AISP
N.D. N.D. Class II GRYRP
N.D. N.D. Class I AISP
N.D. N.D. Class I GDIA
1 Normal Class III AISP
the number refers to the nucleotide of the restriction site in the AAV2
in adenovirus-infected HeLa cells.
dot blot (class II).
id in boldface is a missense mutation.
insertion mutant helper plasmids of pACG2. Cell lysates from 293 cells
, H4047; 8, wild-type were analyzed by acrylamide gel electrophoresis
ase-conjugated secondary antibody. On the left of the Western blot are
tions of the major capsid protein, VP3, and the minor capsid proteins,ABLE 1
pe of A
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278 RABINOWITZ, XIAO, AND SAMULSKIurification technique is not as harsh as CsCl and has
een shown to increase virus recovery by 10-fold (Zolo-
ukhin et al., 1999). However, other class II mutants
emained noninfectious after purification using an iodixa-
ol step gradient (data not shown). Although we deter-
ined that insertion mutant viruses N2944 and H3595
ere infectious using the LacZ transduction assay, it
hould be noted that these mutants resulted in low in-
ectious titers (1 3 102 transducing units/1.75 3 108
articles), similar to those of previously published low
nfectious particle (lip) mutants (Hermonat et al., 1984).
lectron microscopy of class II and class III mutants
To further characterize class II and III rAAV2 insertion
utants for biological differences, we visualized mutant
articles by EM. The EM analysis revealed only gross
FIG. 3. (A) Dot blot hybridization to the LacZ transgene. Cell lysate
ild-type helper plasmids and the LacZ transgene containing vector wer
ere treated with DNase and RNase prior to dot blotting to remove u
raction 1 has a density range of 1.377–1.41, fraction 2 has a densit
-galactosidease gene was used as the control template, to estimate p
f 1000-bp DNA has 9.1 3 1011 molecules. (B) Infection of HeLa cells w
ontaining the LacZ transgene. Cells expressing the transgene appeaorphology of the infectious class III viruses, which were mndistinguishable from wild-type virions (compare Figs. 4A
ith 4B and 4C). Whereas distinct differences were ob-
erved between class II/III mutant virus H3595 when com-
ared to wild-type virions (Figs. 4A and 4F, bottom four
anels). EM images of H3595 revealed a slightly larger
oughly pentagonal outline, while wild-type virus appeared
niformed in size and was hexagonal. Interestingly, class II
utant H2634, which was negative for Vp1 or Vp2 by West-
rn blot (Fig. 2, lane 2), appeared normal in morphology by
M analysis (Fig. 4D). Based on this analysis, virion mor-
hology alone is not sufficient to distinguish class II mu-
ants from class III since small insertions within the capsids
an result in either nondetectable (Figs. 4B–4E) or notice-
ble alterations in virion structure (Fig. 4F, bottom four
anels). However, this approach was able to provide addi-
ional data to our characterization of these linker insertion
enovirus-infected 293 cells transfected with the insertion mutant or
cted to cesium chloride isopycnic gradient. Fractions from the gradient
ged nucleic acids; fraction numbers are labeled above the dot blot.
of 1.39–1.435, and fraction 3 has a density range of 1.42–1.45. The
numbers. Estimates of particle number where derived assuming 1 mg
5 3 108 particles from various insertion mutants and wild-type capsid
hen stained with X-gal.s of ad
e subje
npacka
y range
article
ith 1.7utants (Fig. 4, compare A to F).
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279AAVZ MUTAGENESIS AND VIRUS PRODUCTIONapsid ratio of class II and class III virions
Rose et al. (1971) established that AAV2 particles are
omposed of Vp1, Vp2, and Vp3 at a 1:1:20 ratio (Rose et
l., 1971). In an effort to determine if class II and class III
utant virions maintained this ratio, Western blots were
erformed on the cesium chloride-purified virus. Purified
FIG. 4. Electron microscopy of insertion mutants. Samples (200 ml) of
mM MgCl2, speed-vac desiccated, and then resuspended in 20 ml of d
A) rAAV2 with wild-type virion. Infectious insertion viruses (B) H2690 and
our panels). The black bar in A is 100 nm; the magnification is equiva
FIG. 5. Analysis of virion composition from wild-type and various ins
entrifugation. Peak fractions of virus were determined by dot blot hybr
etween 1.0 3 109 and 2.5 3 109 particles were used. Virions from (1) w
nd (8) N4160 were analyzed by acrylamide gel electrophoresis and im
onjugated secondary antibody. On the right of the Western blot are the
f the major capsid protein, VP3, and the minor capsid proteins, VP2 and VPiruses analyzed by Western blot showed similar
mounts of Vp3 in all mutants sampled (Fig. 5, Vp3
rrow); between 1 3 109 and 2.5 3 109 viral particles
ere used for each sample. The amounts of Vp2 and Vp1
re also nearly equivalent in all test samples, except
2634, where no minor capsid components were ob-
rus from the peak fraction of gradient were dialyzed against 13 PBS 1
H2O. Samples were negatively stained with 2% phosphotungstic acid.
591. Noninfectious viruses (D) H2285, (E) H2634, and (F) H3595 (bottom
each panel.
mutant viruses isolated from cell lysates by cesium chloride gradient
n and dialyzed against 13 PBS 1 1 mM MgCl2. For each, viral sample
rAAV2; (2) H2285; (3) R2349; (4) H2591; (5) H2634; (6) H2690; (7) H3766;
lotting with the B1 monoclonal antibody and detected by peroxidase-
ns of the molecular weight standards and on the left are the positionseach vi
istilled
(C) H2ertion
idizatio
ild-type
munob
positio1.
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280 RABINOWITZ, XIAO, AND SAMULSKIerved (Fig. 5, lane 5). The lack of minor capsid compo-
ents for H2634 is consistent with the Western results
rom cell lysates (Fig. 2). At the limit of detection in this
ssay, the class II insertion mutant H2634 appears to
ssemble AAV virions without Vp1 and Vp2, even though
M analysis suggests that this mutant has normal mor-
hology (Fig. 4D).
eparin binding of class II and class III mutants
Recently our lab established that AAV-2 uses a hepa-
an sulfate proteoglycan as a primary receptor for infec-
ivity (Summerford and Samulski, 1998). To determine
hat role heparin binding may have in class II particles’
nability to infect cells as well as the ability of class III
irus to bind heparin agarose, heparin batch binding
xperiments were performed. Not surprisingly, all class
II mutants were positive for heparin binding, with the
ajority of virus eluting in the 1 M NaCl2 step (data not
hown). To determine if loss of infectivity of class II
utant viruses was related to a lack of heparin binding,
atch binding experiments were analyzed by dot blot
ybridization (Fig. 6). For each of the viral samples
ested, an internal control to determine 100% bound was
potted on the filter independently of heparin binding
Fig. 6, 100% bound). This allowed us to determine the
ercentage of virus retained, at each step of heparin
urification. After binding to heparin agarose, samples
ere washed and then eluted using increasing salt con-
entrations (see Materials and Methods). Recombinant
AV2 with wild-type virion shells demonstrated 90% bind-
ng, with 10% released in the wash, followed by 60%
ecovered in the elution buffer, and 20% remaining bound
o heparin agarose (Fig. 6, lane 1). Class II mutants
2285, H2416, and H2634 demonstrated similar binding
nd elution profiles (Fig. 6, lanes 2–4). However, class II
utant H3761 was distinct in its heparin agarose binding
rofile, with the majority of the virion in the binding buffer
nd the washes (Fig. 6, lane 5). Further analysis is
equired to determine the reason for lack of heparin
inding in this batch assay.
Interestingly, H2634 binds heparin agarose under
hese conditions, which by Western blot does not carry
etectable Vp1 or Vp2 subunits (Fig. 5, lane 4). The lack
f Vp1 and Vp2 in H2634 and its ability to bind heparin
garose suggest that the heparin binding domain may be
ocated in Vp3 capsid proteins.
DISCUSSION
We have used insertional mutagenesis of the struc-
ural coding sequence of AAV serotype 2 in order to
etermine critical capsid domains and positions capable
f tolerating insertions without loss of function. The linker
nsertions isolated were identified in each of the three
AV capsid subunits. Based on Western blot, cesium
hloride isopycnic centrifugation, DNase protection, EM, os well as virus transduction analysis, we separated the
apsid insertion mutants into three classes. The classes
ere distinguished based on whether the mutations re-
ulted in inability to assemble virions (class I), ability to
ackage and protect virion DNA (class II), and finally
bility of assembled virions that protect viral DNA to
nfect target cells (class III).
To carry out this study, we used a cloning strategy that
mployed partial digestion of the capsid coding se-
uences to create a collection of in-frame linker insertion
utants. The restriction enzymes we utilized (HaeIII
laIV, and RsaI) have 43 sites within this region of AAV2.
lthough this strategy appeared straightforward, of the
nzymes chosen, only HaeIII did not show a site prefer-
nce. The restriction enzyme NlaIV showed a 25% site
reference for position 4160, while RsaI displayed a 45%
ite preference for position 3391. These site preferences
ampered the inclusion of all 43 potential insertion sites
n this study (Table 1). Regardless of these limitations, we
ere able to generate 22 insertion mutants that spanned
ll three capsid coding domains (Fig. 1). A critical aspect
FIG. 6. Analysis of wild-type and noninfectious insertion mutant virus
atch binding to heparin agarose by dot blot hybridization. Viruses with
ild-type virions and insertion in the capsids were dialyzed against
.53 PBS and 0.5 mM MgCl2. One hundred microliters of each virus
as bound to 100 ml of heparin agarose at room temperature for 1 h.
amples were washed six times with 500 ml of wash buffer each,
ollowed by elution with 100 ml of 0.5, 1.0, and 1.5 M NaCl each, and the
upernatant from each wash and elution step was saved. Twenty
icroliters of supernatant from each step and 20 ml of the agarose
ellet were used for dot blot hybridization. Pairs of washes were
ombined and 1⁄50 of the total volume from each pair was used for dot
lot hybridization, while 1⁄5 of the elution supernatant and agarose bed
olumes was used. The 100% bound was equivalent to l⁄5 of the virus
dded to the heparin agarose. Samples were (1) rAAV2 with wild-type
irion; (2) H2285; (3) H2416; (4) H2634; and (5) H3761.f this approach was the choice of the EcoRV restriction
s
i
p
w
t
b
i
l
m
i
c
i
c
i
l
t
s
C
i
n
d
t
i
a
d
t
t
t
T
a
1
v
s
t
d
m
W
t
w
f
a
a
w
e
V
c
r
a
t
S
m
r
b
C
p
n
t
s
e
w
(
a
p
f
a
m
s
(
f
H
c
h
V
r
a
c
t
a
1
a
A
o
p
c
V
1
s
s
a
b
p
r
A
d
d
i
u
m
v
a
T
f
281AAVZ MUTAGENESIS AND VIRUS PRODUCTIONite as part of the linker insertion. The sequence of this
nsert was chosen for two reasons: (1) EcoRV is not
resent in the AAV genome and (2) the 12-bp insertion
ould not produce a stop codon within any frame using
hese restriction enzymes. Incorporation of Kanr gene
etween two EcoRV restriction sites allowed for easy
solation of plasmids carrying novel insertions (drug se-
ection in E. coli). The Kanr coding sequences was re-
oved by EcoRV digestion and reforming a single 12-bp
nsertion site containing a unique EcoRV site within the
apsid gene (Fig. 1). Following detailed mapping of linker
nsertion sites, the capsid coding sequences were sub-
loned into AAV helper plasmids previously established
n our lab and assayed for AAV2 vector production. Uti-
izing the linker-modified helper plasmids, we were able
o test rAAV vectors for virion assembly, capsid compo-
ition, stability, heparin binding, and infectivity.
lass I insertion mutants
Of the 22 capsid insertion mutants isolated, 7 were
dentified with a class I phenotype. Class I mutants did
ot protect the viral genome as assayed by DNase and
ot blot hybridization of cesium chloride gradient frac-
ions (data not shown). This class of capsid mutants may
nclude both packaging and assembly defects. Addition-
lly, some class I mutants may have reduced stability
uring purification through cesium chloride or tempera-
ure-dependent assembly. While we did not characterize
hese capsid variants further, these mutants are similar
o cap mutants first described by Hermonat et al. (1984).
he mutants described by Hermonat et al. (1984) were
lso defective for virus production (Hermonat et al.,
984). Although defective for production of stable AAV
irions, these mutants may be important reagents for
tudying AAV maturation.
For example, studies examining the subcellular loca-
ion of wild-type AAV2 capsid subunits resulted in Vp3
ispersed throughout the cell, while Vp1 and Vp2 accu-
ulate in the nucleus (Hunter and Samulski, 1992;
istuba et al., 1997). Using a conformation-specific an-
ibody against assembled AAV2, nucleolar localization
as shown (Wistuba et al., 1997), similar to previous
luorescent antibody assays against AAV virions (Hunter
nd Samulski, 1992). Furthermore, when individual Vp1
nd Vp2 capsid subunits were expressed in HeLa cells,
ild-type patterns of distribution were observed. How-
ver, only when Vp3 was expressed in the presence of
p1 or Vp2 did this protein also accumulate in the nu-
leus as previously described (Ruffing et al., 1992). These
esults suggest that interactions between the subunits
re important for the assembly of AAV2 particles even in
he absence of terminal repeats or rep protein functions.
imilar analysis of class I capsid subunit distribution
ay help demonstrate the presence of domains that are fesponsible for proper nuclear localization and assem-
ly.
lass II insertion mutants
The class II insertion mutants isolated in this study
rotect the viral genome in a DNase assay, but are
egative for virus infection. By Western blot analysis
hese mutants appear to assemble the virion with the
ame stoichiometry as wild-type virions (Fig. 2), with the
xception of H2634. The linker insertions for this class
ere also distributed across all three capsid subunits
Table 1). The class II mutants described in this study
ppear distinct from the cap mutant category described
reviously (Hermonat et al., 1984), in that although de-
ective for infectious virions, these mutants accumulate
nd protect ssDNA. In addition, the majority of these
utants were positive for retention to a heparin column,
uggesting that binding to the AAV primary receptor
heparan sulfate) was not a rate-limiting step (Summer-
ord and Samulski, 1998). Surprisingly, one mutant,
2634, did not appear to express Vp1 and Vp2 in either
ell lysates (Fig. 2) or purified virions (Fig. 5) but bound
eparin sulfate similarly to the wild-type (Fig. 6). Although
p1 and Vp2 could not be detected, EM analysis did not
eveal any gross alteration in morphology (Fig. 4D). The
bsence of Vp1 and Vp2 is difficult to explain since it
ontradicts the requirement of these proteins to seques-
er Vp3 in the nucleus, as previously described (Hunter
nd Samulski, 1992; Ruffing et al., 1992; Wistuba et al.,
997). Although H2634 inserts an ADIG and the aspartic
cid results in a net negative charge, the position of the
DIG is directly downstream of two lysines. The insertion
f ADIG may cause a local misfolding of the capsid
rotein, exposing these or other lysines to ubiquitin-
onjugating enzymes, thereby altering the half-life of
p1 and Vp2 but not Vp3 (Hershko and Ciechanover,
992). It is plausible that Vp1 and Vp2 are still able to
equester Vp3 to the nucleus for assembly but their
hortened half-life reduces their incorporation in the
ssembled virion to levels undetectable by Western
lots.
Since the class II mutants bound heparin, the loss of
roductive infection to HeLa and 293 cells appears un-
elated to receptor binding. The viral entry pathway of
AV2 has not been extensively studied. Recent work has
emonstrated that AAV2 enters the cell through an en-
osome and is released in a pH-dependent manor. This
s followed by migration to the perinuclear space and
ncoating in productive infections (Barlett, personal com-
unication). A similar pathway is used by canine parvo-
irus, suggesting conservation in entry mechanism
mong these parvoviruses (Vihinen-Ranta et al., 1998).
he ability of class II mutants to bind heparin sulfate but
ail to transduce target cells suggests a blocked in in-
ection that may occur at any step from viral entry to
u
s
i
s
w
t
m
t
t
C
t
n
c
(
4
e
t
d
i
a
i
m
P
s
t
s
p
y
i
w
t
t
t
p
a
(
R
t
1
r
d
u
v
m
m
w
i
d
a
t
H
w
i
w
p
p
a
(
t
i
o
a
1
t
c
d
T
g
t
E
d
d
a
n
s
p
p
i
t
m
b
v
r
r
a
c
m
R
d
h
d
s
m
a
d
T
Å
c
m
c
i
i
i
i
a
282 RABINOWITZ, XIAO, AND SAMULSKIncoating. Recently, we demonstrated the ability to as-
ay early steps in AAV entry using fluorescent virus
nfused in rat brain (Bartlett and Samulski, 1998). These
tudies determined that the virus bound to target cells
ithin 10 min, followed by transport to the nucleus within
he first hour postinfection. Similar analysis using these
utants should be extremely helpful in better defining
he defects of these mutants in early steps of AAV infec-
ion.
lass III insertion mutations
The class III mutants were unique in that they pro-
ected the viral genome and retained infectivity at levels
ear that of wild-type virus (Fig. 3B). Similar to class II,
lass III mutants protected viral DNA, bound heparin
data not shown), had normal morphologies by EM (Fig.
B), and were derived from linker insertions positioned in
ach of the three capsid subunits (Table 1). The charac-
erization of these capsid mutants represents the first
escription of AAV virions that can tolerate amino acid
nserts without interfering with normal viral infectivity. In
ddition, these mutants validate the concept of express-
ng foreign epitopes on the surface of AAV capsids that
ay influence normal infectivity, such as retargeting.
revious modifications with B19 Vp1 and egg white ly-
ozyme fusion proteins resulted in virus-like particles
hat retain lysozyme enzyme activity. While these data
upported the ability to form capsid fusion proteins, the
articles generated were empty and not infectious (Mi-
amura et al., 1994). The viable class III mutants isolated
n this study ranged from 5% (H2690) to 100% (N4160) of
ild-type infectivity. Understanding the distinction be-
ween low infectious particles and high transducing par-
icles should help determine critical steps in AAV infec-
ion. In addition, the wild-type viable insertion mutants
rovide a unique opportunity to test insert size limitation
s well as ligand-specific retargeting of modified virions
Rabinowitz and Samulski, manuscript in preparation).
ecently, the sequence and viral tropism of AAV sero-
ypes 4 and 5 have been characterized (Chiorini et al.,
999, 1997). These viruses do not appear to utilize hepa-
an sulfate as a receptor for infection, and therefore
omain swapping between serotypes should provide a
nique opportunity to identify amino acids specific for
iral binding to target cells (Rabinowitz and Samulski,
anuscript in preparation). Detailed analysis of these
utants should provide a better understanding of both
ild-type and vector-modified infection.
Two mutants (H/N2944 and H3595), which were first
dentified as class II after CsCl2 gradient purification,
emonstrated a class III phenotype when isolated using
n iodixanol step gradient. Interestingly, mutants of this
ype have been described as lip (Hermonat et al., 1984).
owever, unlike the lip mutants of Hermonat et al. (1984),
hich were positioned solely within the Vp1 unique cod- Tng region (Hermonat et al., 1984), H/N2944 and H3595
ere localized to Vp3. Interestingly, mutant H3595 dis-
layed morphological differences by EM when com-
ared to wild-type virions. This mutant had a pentagonal
ppearance and was slightly larger than the wild-type
Fig. 4D). Because the H3595 insertion is within a puta-
ive loop domain of Vp3 coding sequences, the alteration
s present in all 60 subunits and results in the insertion
f amino acids GRYRP (Table 1). A comparison of CPV
nd FPV crystal structures has determined that 5 of the
0 amino acid differences in Vp2 are on the surface of
he virion (Llamas-Saiz et al., 1996). One of these
hanges, 375 N-D, causes a displacement of 7 Å in the
omain between loops 3 and 4 (Agbandje et al., 1993).
hese examples demonstrate the significance of both
enetic and crystal analysis when studying virion struc-
ure and function. The alteration seen with this virion by
M and lip phenotype observed after infection maybe
ue to the amino acid insertion interfering with capsid
omain folding, number of assembled subunits, and or
ssembly symmetry. The exact explanation of this phe-
otype will require information obtained from AAV crystal
tructure analysis.
The availability of crystal structures for some of the
arvoviruses has complemented genetic studies and
rovided sufficient detail to test critical domains involved
n entry and infectivity. The parvovirus B19 crystal struc-
ure has been determined to 8 Å (Chapman and Ross-
ann, 1993). Although there is only a 15% overall identity
etween B19 and the feline panleukopenia virus (FPV)
irion, the core antiparallel b-barrel of B19 is similar with
espect to the overall symmetry of the antiparallel b-bar-
el in FPV (Agbandje-McKenna et al., 1994). The eight
ntiparallel b-strands form a barrel domain that is well
onserved not only among parvoviruses but also among
any types of viruses (Chapman and Rossmann, 1993;
ossmann, 1989). The crystal structure of CPV has been
etermined at 2.8 Å (Tsao et al., 1991). This information
as allowed the precise positioning of amino acid resi-
ues with respect to the surface domains of the viral
ubunit. Amino acids 93 and 323 of CPV are required for
aintenance of host range infectivity (Chang et al., 1992),
nd from the crystal structure, these regions have been
etermined to be part of loops 1 and 3 (Tsao et al., 1991).
he crystal structure of FPV has been determined at 3.3
(Agbandje et al., 1993).
In summary, we have generated a collection of AAV
apsid mutants that fall into three phenotypes; class I
utants, which are defective for producing stable virions,
lass II mutants, which assemble noninfectious DNA
ntact virions, and class III mutant virions, which are
nfectious. We believe that these capsid mutants will be
mportant reagents for analyzing basic questions of AAV
nfections that focus on virion assembly, receptor-medi-
ted entry, uncoating, and viral transgene expression.
he importance of understanding these fundamental
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283AAVZ MUTAGENESIS AND VIRUS PRODUCTIONteps in AAV entry is best illustrated by recent studies
sing AAV vectors for cystic fibrosis gene therapy. These
ectors have met with limited success due to the inability
o infect target cells (Bartlett et al., in preparation). The
vailability of these AAV class II and III capsid mutants
ill be valuable substrates for engineering rAAV vectors
ith novel targeting capabilities. In addition to deriving
argeting vectors, further characterization of mutant cap-
ids as well as the elucidation of the AAV crystal struc-
ure should provide a detail paradigm for AAV viral as-
embly and entry.
MATERIALS AND METHODS
ells and viruses
Human 293 and HeLa cells were maintained at 37°C
ith 5% CO2 saturation in 10% fetal bovine serum (Hy-
lone) in Dulbecco’s modified Eagle’s medium (Gibco
RL), with streptomycin and penicillin (Linberger Com-
rehensive Cancer Center, Chapel Hill, NC). Four 3 106
93 cells were plated the day before transfection onto a
0-cm plate. Cells were transfected by both calcium
hosphate (Gibco BRL) and Superfection (Qiagene) ac-
ording to manufacturers’ specifications. The insertional
utant packaging plasmids, described below, were
ransfected along with pAB11, containing the CMV-driven
ac Z gene with a nuclear localization signal. For each
ransfection the same amounts of packaging plasmid (12
g) and pAB11 (8 mg) were used for each 10-cm plate.
or each transfection an additional plate was used con-
aining the transgene plasmid only to assess transfor-
ation efficiencies. After transfection the cells were in-
ected with helper virus Ad5 dl309 at an M.O.I. of 5, and
8 h later the cells were lysed and the virus was purified.
Recombinant virus was purified using cesium chloride
sopycnic or iodixanol gradients. In both cases cells
ere centrifuged at 1500 rpm (Sorvall RT 6000B) for 10
in at 4°C. Proteins were precipitated from the super-
atant using ammonium sulfate (30% w/v) and resus-
ended in 13 phosphate-buffered saline (PBS) (137 mM
aCl, 2.7 mM KCl, 4.3 mM Na2HPO4 7H2O, 1.4 mM
H2PO4). The cell pellet was resuspended in 13 PBS
ontaining 0.1 mg/ml DNase I (Boehringer-Mannheim)
ysed by three freeze–thaw cycles, combined with the
rotein portion of the supernatant, and incubated at 37°C
or 30 min. This material was subjected to sonication
Branson Sonifier 250, VWR Scientific), 25 bursts at 50%
uty, output control 2. Cell debris was removed by cen-
rifugation (Sorvall RT 6000B). To each milliliter of super-
atant 0.6 g of CsCl was added and the solution was
entrifuged for 12–18 h (Beckman Optima TLX ultracen-
rifuge) in a TLS 55 rotor at 55,000 rpm. Alternatively, the
upernatant was layered on top of an Iodixanol (Opti-
rep-Nycomed Pharma As, Oslo, Norway) gradient of 60,
5, 30, and 15. This gradient was centrifuged in a Beck-
an Optima TLX ultracentrifuge using a TLN 100 rotor at00,000 rpm for 1 h. Fractions were recovered from these
radients and 10 ml from each fraction was utilized for
ot blot hybridization to determine which fraction con-
ained the peak protected virion (see Titration of recom-
inant virus).
onstruction of AAV packaging plasmids
The capsid domain of pAAV/Ad was cloned into pBS1
Stratagene) using HindIII, resulting in pAV2Cap. Partial
igestion of pAV2Cap using the restriction enzymes
aeIII, NlaIV, and RsaI and gel purification of the unit-
ength DNA fragment resulted in the isolation of the
tarting material for cloning. The aminoglycoside 39-
hosphotransferase gene, conferring kanamycin resis-
ance (Kanr), from pUC4K (Pharmacia) digested with SalI
as flanked by linkers containing NaeI and EcoRV sites,
SalI overhang at one end, and an EcoRI overhang at the
ther end (top 59-AATTCGCCGGCGATATC-39, bottom 59-
CGAGATATCGCCGGC-39). This fragment was cloned
nto the EcoRI site of pBluescript (SK1) (Stratagene).
igestion with NaeI released the Kanr gene, and this
ragment was ligated into the pAV2Cap partials. The
esulting plasmids were screened for insertion into the
apsid domain and then digested with EcoRV to remove
he kanr gene, leaving the 12-bp insertion 59-GGC-
ATATCGCC-39 within the capsid domain. Multiple en-
yme digests and DNA sequencing were used to deter-
ine the position of the 12-bp insertion within the capsid
oding domain. The enzyme digests included EcoRV/
anII, EcoRV/BstNI, EcoRV/PstI, and EcoRV/HindIII. The
apsid domains of the resulting plasmids were digested
ith Asp718 and subcloned into the pACG2 packaging
lasmid, with the exception of one NlaIV clone that over-
apped the 39-Asp718 site. This insertion mutant was
loned into pAAV/Ad using a HindIII/NsiI digestion.
estern blotting
Cell lysates after freeze–thaw lysis and sonication was
entrifuged to remove large cell debris. Twenty microli-
ers of supernatant was immediately added to 20 ml of
3 SDS gel loading buffer containing dithiothreitol and
oiled for 5 min. Proteins were analyzed by SDS–poly-
crylamide gel electrophoresis and transferred to nitro-
ellulose electrophoretically. The nitrocellulose mem-
ranes were immunoblotted using the anti-Vp3 monoclo-
al antibody B1 (a generous gift from Jurgen A.
leinschmidt). Each of the insertion mutants was tested
t least twice by Western blot analysis. The secondary
nti-mouse horseradish peroxidase IgG was used to
ndirectly visualize the protein by enhanced chemilumi-
escence (ECL, Amersham). The Western blots were
canned from enhanced chemiluminescence-exposed
ioMax film (Kodak) into Adobe PhotoShop and analyzed
y ImageQuaNT software (Molecular Dynamics Inc.).Viral proteins were visualized by Western blotting fol-
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284 RABINOWITZ, XIAO, AND SAMULSKIowed by immunoblotting as described above. Between
.0 and 2.5 3 109 viral particles were used for each
ample. The virus was isolated from the peak cesium
radient fraction as determined by dot blot and dialyzed
gainst 0.53 PBS containing 0.5 mM MgCl2 prior to
olyacrylamide gel electrophoresis.
itration of recombinant virus
Fractions from CsCl gradients were obtained by
eedle aspiration. The refractive index was obtained
sing a refractometer (Leica Mark II), and the index
as used to determine the density of fractions. Ali-
uots of 10 ml from fractions between 1.36 and 1.45
/ml were tested for the presence of protected parti-
les by dot blot hybridization. The aliquots were di-
uted 1:40 in viral dilution buffer (50 mM Tris–HCl, 1
M MgCl2, 1 mM CaCl2 10 mg/ml RNase, 10 mg/ml
Nase) and incubated at 37°C for 30 min. To the
amples sarcosine (final concentration 0.5%) and
DTA (final 10 mM) were added and incubated at 70°C
or 10 min. Proteinase K (Boehringer-Mannheim) was
dded to a final concentration of 1 mg/ml and the
amples were incubated at 37°C for 2 h. Following this
ncubation the samples were denatured in NaOH (350
M final) and EDTA (25 mM final). The samples were
pplied to equilibrated Nytran (Gene Screen Plus,
EN Life Science Products) using a dot blot manifold
Minifold I, Schleicher & Schuell). The membrane was
robed with a random-primed (Boehringer-Mannheim)
32P]dCTP-labeled LacZ DNA fragment. The mem-
ranes were exposed to film (BioMax MR, Kodak) or to
hosphor imagining screens (Molecular Dynamics)
nd intensity estimates were done using ImageQuant
oftware (Molecular Dynamics). Peak fraction of virus
ere then dialyzed in 13 PBS for transducing titer.
Transductions titers were determined by histochemi-
al staining for LacZ activity. HeLa cells had been in-
ected with Ad dl309 at a m.o.i. of 5 for 1 h. The cells were
hen washed with 13 PBS and fresh medium was added.
liquots of virus from peak fractions, equivalent to 1.75 3
08 particles, were used to infect HeLa cells. Twenty to
wenty-four hours later cells were washed with 13 PBS,
ixed (2% formaldehyde, 0.2% gluteraldehyde in 13 PBS),
ashed, and stained with 59-bromo-4-chloro-3-indoly-b-
-galactopyranoside (Gold Bio Technology) dissolved in
,N-dimethyl formamide (Sigma) diluted to 1 mg/ml in
3 PBS, pH 7.8, 5 mM potassium ferricyanide, 5 mM
otassium ferrocyanide, 2 mM MgCl2 at 37°C for 12–24
. Stained HeLa cells were counted in ten 4003 micro-
cope fields. The transducing number was determined
y averaging the number of stained cells in 10 fields,
ultiplying by the number of fields on the plate, and
ividing that number by the number of nanograms of
rotected template. Blectron microscopy
Peak fractions of rAAV with wild-type virion or mu-
agenized virions were dialyzed in 0.53 PBS containing
.5 mM MgCl2. The virus was placed on a 400-mesh
low-discharged carbon grid by inverting on a 10-ml drop
f virus for 10 min at room temperature, followed by three
3 PBS washes for 1 minute each. The virus was stained
n 2% phosphotungstic acid for 1 min. Specimens were
isualized using a Zeiss EM 910 electron microscope.
eparin agarose binding assay
Recombinant virus containing wild-type capsids or in-
ertion in the capsids were dialyzed against 0.53 PBS
ontaining 0.5 mM MgCl2. One hundred microliters of
ach virus was bound to 100 ml of heparin agarose type
(H-6508, Sigma, preequilibrated in 20 vol of 0.53 PBS
ontaining 0.5 mM MgCl2) at room temperature for 1 h in
1.5-ml microfuge tube. After each step, binding washes
nd elutions samples were centrifuged at 2000 rpm (Sor-
all MC 12V) for 2 min to collect supernatant. Samples
ere washed six times with 0.5 ml of 0.53 PBS contain-
ng 0.5 mM MgCl2, and the supernatants collected. Sam-
les were eluted in three steps of 100-ml volumes con-
aining 0.5, 1.0, and 1.5 M NaCl in 0.53 PBS containing
.5 mM MgCl2 and the supernatants collected. For each
ample 20 ml of supernatant from each step was used for
ot blot hybridization. The 100% bound control was an
nternal standard equivalent to one fifth of each input
irus used in the dot blot. The heparin agarose viral
ixtures were washed six times with 0.53 PBS, 0.5 mM
gCl2 in volumes that resulted in a 1:15,625 dilution.
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